An Alzheimer’s vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease, the company said on Monday.
The companies developing aducanumab, Biogen and its partner Eisai, announced that they halted two late-stage trials of the experimental drug after an independent group’s analysis showed that the trials were unlikely to “meet their primary endpoint.”
The Cambridge, Massachusetts-based biotech giant joins a long list of companies in the last decade that have failed to find a treatment for Alzheimer’s.
Check out the project in the link for today. The claim is a novel process to find a way to immunize against Alzheimer’s disease. Not sure how this low budget will win from all the billions already spent by the large pharmaceutical companies but see for yourself.
A new drug shows promising results: Early results indicate that the drug could reverse natural, age-related cognitive decline. Researchers also believe that it might help patients whose memories are impaired because of conditions such as depression, schizophrenia and Alzheimer’s disease.
Interesting, the video on the page in the link for today highlights life style changes while the words on the site talk about a new compound that has been found that could prevent Alzheimer’s. Both are interesting to read/watch.
It has been known that people can be disoriented after general anesthesia but now a study found that propofol (a very common drug to use) also disrupts presynaptic mechanisms, probably affecting communication between neurons across the entire brain in a systematic way that differs from just being asleep. In this way it is very different than a sleeping pill
In a new study, a Salk team found that J147 binds to a protein called ATP synthase, which is responsible for producing a common cellular “energy currency” known as ATP. This protein is known to control aging in worms and flies, and the researchers found that by binding to it the drug was able to prevent age-related damage to the brain.
Novel Drug Shows Promising Results in Alzheimer’s Model
Scientists report that a novel small-molecule drug, which works by stopping toxic ion flow in the brain that is known to trigger neuronal apoptosis, can restore brain function and memory in a mouse model of Alzheimer’s disease (AD). The team believes the drug could be used to treat AD and other neurodegenerative diseases such as Parkinson’s and amyotropic lateral sclerosis (ALS).
You would think that all would be working cooperatively towards a solution for Alzheimer’s but this is not the case. The ridiculous costs and time that it takes to run effective tests lead to a short time to recoup your research costs when you would find a workable solution. Researchers can not make a good case that this is a wise investment for Pharmaceutical companies.
So something is really wrong here and the government should look into this.
Buildups of “clumpy” proteins in the brain are well-known hallmarks of Alzheimer’s, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
Dr. Debbie Toiber, of the BGU Department of Life Sciences, and her team discovered that a specific protein — Sirtuin-6 (SIRT6) — is severely reduced in the brains of Alzheimer’s patients. SIRT6 is critical to the repair of DNA, the deterioration of which “is the beginning of the chain that ends in neurodegenerative diseases in seniors,” she explains.
The blood-brain barrier prevents us from simply being able to inject the protein into the brain to replenish its supply. Dr. Toiber is currently working on finding a way to increase the expression of the protein into the brain.